Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
Status:
Completed
Trial end date:
2016-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of
MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) +
grazoprevir (MK-5172) + ruzasvir (MK-8408) in participants with moderate (Part 1) and severe
(Part 2) renal insufficiency (RI) to plasma PK in healthy participants.